Table 2.
Linear regression analysis between R21X carrier status and Lp(a) levels
| Population | Carriers [n] | n | β* | 95% CI lower bound* | 95% CI upper bound* | SE* | p† | R2† | I2|| |
|---|---|---|---|---|---|---|---|---|---|
| GCKD | 74 | 4771 | − 13.0‡§ | − 20.0 | − 6.0 | 3.6 | 4.34e−12 | 0.011 | – |
| KORA F3 | 56 | 3099 | − 12.6 | − 19.5 | − 5.7 | 3.5 | 6.50e−11 | 0.013 | – |
| KORA F4 | 63 | 3040 | − 9.9 | − 16.0 | − 3.8 | 3.1 | 3.95e−12 | 0.015 | – |
| Meta-analysis | 193 | 10,910 | − 11.7 | − 15.5 | − 7.8 | 1.9 | 3.39e−32 | – | 0.0 |
Lp(a) concentrations are given as mg/dL. The β estimate is given on the original scale (mg/dL). Age- and sex-adjusted model
n number
*On the original scale
†On the inverse normal transformed scale
‡GCKD additionally adjusted for eGFR: beta = − 12.4 [− 19.58; − 5.25], SE = 3.7, p = 3.16e−10
§GCKD additionally adjusted for eGFR and urine albumin-to-creatinine ratio: beta = − 13.12 [− 20.22; − 6.02], SE = 3.6, p = 1.08e−10
||Heterogeneity was 0.0 on the original and on the inverse normal transformed scales